Aristeia Capital’s Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 CND.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,069,338
Closed -$2.85M 935
2021
Q4
$2.85M Hold
1,069,338
0.05% 348
2021
Q3
$1.9M Buy
1,069,338
+643,588
+151% +$1.2M 0.04% 332
2021
Q2
$426K Buy
+425,750
New +$359K 0.01% 406

Other funds holding CND.WS

Aristeia Capital's CND.WS Position: Q1 2022 in Review

Aristeia Capital sold out of Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 (CND.WS) in Q1 2022, closing a stake of 1,069,338 shares — an estimated $2.85M sold.

Aristeia Capital first reported a position in CND.WS in Q2 2021 and held it in 3 quarters. The position peaked at $2.85M in Q4 2021. 21 funds tracked by Wall St. Rank hold CND.WS as of Q1 2022.

  • Aristeia Capital reported no remaining Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position as of Q1 2022 after selling out during the quarter.
  • Aristeia Capital sold 1,069,338 Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 shares in Q1 2022, an estimated $2.85M.
  • Aristeia Capital first reported a position in Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 in Q2 2021 and held it in 3 quarters.
  • Aristeia Capital's Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position peaked at $2.85M in Q4 2021.
  • 21 funds tracked by Wall St. Rank held Concord Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 as of Q1 2022.

Based on Aristeia Capital's 13F filing for Q1 2022, filed 16 May 2022.